Based on KEYNOTE-811, would you add pembrolizumab for HER2+ distal esophageal adenocarcinoma with new supraclavicular lymph nodes if treated previously with concurrent chemoradiation and PD-L1 CPS of 3?
Answer from: Medical Oncologist at Community Practice
There are a few important pieces of information needed to make a good therapeutic decision in this case:
Age and comorbidities of the patient, performance status.
Duration of progression free interval since finishing Chemo-Rads.
What kind of imaging is done to assess extent of disease.
...
Comments
Medical Oncologist at Mayo Clinic All of these are good points! While it is true, at...
Answer from: Medical Oncologist at Academic Institution
There has been an explosion of new positive data in gastroesophageal cancer and keeping up with the data has been dizzying. The KEYNOTE-811 data established CAPEOX + trastuzumab + pembrolizumab (regardless of PD-L1 CPS status) as the standard of care for HER-2 positive disease. The data that the que...
Comments
Medical Oncologist at Mayo Clinic My apologies for misreading the question as it rel...
All of these are good points! While it is true, at...